Neglected Tropical Diseases Diagnosis Market Size and Outlook 2031

Report Description

Forecast Period	2027-2031
Market Size (2025)	USD 6.28 Billion
CAGR (2026-2031)	4.14%
Fastest Growing Segment	Hospital/Clinics
Largest Market	North America
Market Size (2031)	USD 8.01 Billion

Market Overview

The Global Neglected Tropical Diseases Diagnosis Market will grow from USD 6.28 Billion in 2025 to USD 8.01 Billion by 2031 at a 4.14% CAGR. The Global Neglected Tropical Diseases Diagnosis Market encompasses a specialized range of diagnostic technologies, including rapid diagnostic tests, molecular assays, and microscopy solutions, designed to identify parasitic, viral, and bacterial pathogens in low-resource settings. The primary drivers fueling market growth include the rigorous implementation of the World Health Organization’s 2030 Roadmap, which prioritizes disease elimination, alongside strengthening public-private partnerships that enhance healthcare infrastructure. Furthermore, the integration of routine screening into national universal health coverage strategies supports sustained demand for accessible testing mechanisms. According to the World Health Organization, in 2023, an estimated 1.495 billion people globally required interventions against neglected tropical diseases, highlighting the critical necessity for robust diagnostic capabilities to manage this substantial disease burden.

Despite this progress, a significant challenge impeding market expansion is the financial sustainability of diagnostic programs in endemic regions. Reliance on external donor funding often creates volatility in procurement supply chains, while limited domestic health budgets restrict the consistent acquisition and deployment of testing supplies. This economic constraint, coupled with logistical complexities in remote areas, threatens to stall the scalability of essential diagnostic initiatives required for broader market reach.

Key Market Drivers

Growing international funding and philanthropic support play a pivotal role in accelerating the Global Neglected Tropical Diseases Diagnosis Market by bridging the financial gap for research and development. This influx of capital enables the creation of affordable, high-performance diagnostic tools tailored for low-resource settings, while also supporting the scale-up of manufacturing capabilities. For instance, according to the GHIT Fund, October 2025, in the 'Total Investment of Approx. USD 11.6 Million in TB and NTD R&D projects' press release, the organization awarded approximately USD 11.6 million to strengthen product development pipelines for tuberculosis and neglected tropical diseases. Such financial commitments are essential for de-risking the development of novel diagnostics and ensuring that testing solutions reach remote communities where market forces alone often fail to incentivize innovation.

Robust government initiatives and disease elimination programs further propel market expansion as nations align with the World Health Organization’s 2030 Roadmap. These state-led efforts necessitate widespread surveillance and confirmation testing to validate disease clearance, directly driving the procurement of rapid diagnostic tests and molecular assays. According to Uniting to Combat NTDs, January 2025, in the '2024: A year in review' article, a total of 54 countries have successfully eliminated at least one neglected tropical disease, underscoring the success of these rigorous testing-and-treat strategies. However, the need for sustained diagnostic vigilance remains acute given the immense scale of the affected demographic. According to the Drugs for Neglected Diseases initiative, June 2025, in the '2024 Annual Report', globally, half a billion children are impacted by neglected tropical diseases, highlighting the persistent demand for pediatric-adapted diagnostic solutions to maintain elimination gains.

Download Free Sample Report

Key Market Challenges

The financial sustainability of diagnostic programs in endemic regions represents a critical barrier impeding the growth of the Global Neglected Tropical Diseases Diagnosis Market. Because the sector heavily relies on external donor funding rather than recurring commercial revenue, procurement cycles are often irregular and unpredictable. This volatility prevents manufacturers from scaling production and discourages long-term investment in distribution networks, as demand is frequently dictated by the availability of international aid rather than actual clinical necessity. When donor priorities shift or global budgets contract, testing initiatives in low-resource settings face immediate shortages, disrupting the continuity of disease monitoring.

This economic dependence is particularly damaging given recent contractions in global health financing. According to the World Health Organization, in 2025, official development assistance specifically for neglected tropical diseases decreased by 41% between 2018 and 2023. This substantial reduction in external support exposes the fragility of the market, as limited domestic health budgets in affected nations are often unable to bridge the capital gap. Consequently, the inability to secure consistent funding models stalls the broader deployment of essential diagnostic tools, directly restricting the market's potential for expansion.

Key Market Trends

The integration of Artificial Intelligence in microscopy automation is emerging as a transformative trend, addressing the critical shortage of skilled diagnosticians in endemic regions by automating the detection of parasitic pathogens. This technology utilizes advanced algorithms to analyze digital sample images, significantly reducing manual error and increasing diagnostic throughput for diseases such as schistosomiasis and soil-transmitted helminthiasis. Highlighting the collaborative push for this innovation, according to ISGlobal, September 2025, in the 'The MultiplexAI Project Aims to Transform Parasitic Disease Diagnosis with AI' press release, a consortium of nine African and European institutions launched a major initiative to develop and validate these mobile-connected AI tools for primary care settings.

Simultaneously, the widespread adoption of multiplex lateral flow assays is enabling the concurrent detection of multiple neglected tropical diseases at the point of care. These sophisticated rapid tests are vital for decentralized screening models, allowing healthcare workers to make immediate treatment decisions without relying on distant laboratory infrastructure. The scale of this operational shift is substantial; according to the World Health Organization, October 2025, in the 'Global report on neglected tropical diseases 2025', the organization facilitated the procurement of over 1 million diagnostics tests for five specific NTDs in 2024. This volume reflects the growing reliance on versatile rapid diagnostics to support transmission interruption in remote communities.

Segmental Insights

The Hospital and Clinics segment stands as the fastest-growing category in the Global Neglected Tropical Diseases Diagnosis Market. This robust expansion is fueled by the strategic shift towards integrating disease management into national primary healthcare systems, a key objective advocated by the World Health Organization. As governments increase investment in permanent medical infrastructure, hospitals are becoming the central hubs for administering reliable molecular and serological tests. This transition from isolated vertical programs to comprehensive facility-based care ensures that patients in endemic regions receive timely detection for complex conditions, thereby driving the sustained demand for hospital-based diagnostic services.

Regional Insights

North America leads the Global Neglected Tropical Diseases Diagnosis Market due to a well-established healthcare infrastructure and substantial investment in research and development. The region benefits from the presence of major diagnostic manufacturers and rigorous regulatory frameworks managed by the United States Food and Drug Administration, which ensure the reliability of new testing products. Additionally, significant government funding for global health initiatives drives the continuous demand for accurate diagnostic methods. These factors collectively create a supportive environment that secures the dominant market position of North America in this sector.

Recent Developments

In March 2025, the Global Health Innovative Technology (GHIT) Fund announced a significant investment of approximately JPY 780 million ($5.2 million) in two projects focused on developing new diagnostics for schistosomiasis. These projects were led by Drugs & Diagnostics for Tropical Diseases (DDTD) in collaboration with Medical & Biological Laboratories (MBL), a Japanese manufacturer of clinical diagnostic reagents. The funding was directed toward advancing a rapid diagnostic test (RDT) for Schistosoma mansoni and developing a new serological RDT for Schistosoma haematobium, aiming to provide low-cost, point-of-care tools to support disease surveillance and elimination efforts in endemic areas.
In September 2024, QIAGEN announced the expansion of its strategic partnership with Bio-Manguinhos/Fiocruz, a major public health institute in Brazil, to enhance the detection of mosquito-borne diseases. Under this collaboration, the partners agreed to develop and supply advanced molecular diagnostic kits specifically designed to detect dengue and malaria, supporting Brazil's national screening and surveillance programs. The initiative utilized QIAGEN's chemical components and expertise to create localized testing solutions that could effectively monitor and control the outbreaks of these neglected tropical diseases across the region.
In April 2024, Kephera Diagnostics announced the commercial launch of the TESA Immunoblot, a new serological test for Chagas disease, from its CLIA-certified laboratory. This launch marked a significant advancement in the market as it allowed the company to offer a complete, three-test serodiagnostic algorithm necessary for the accurate confirmation of the disease, which is caused by the parasite Trypanosoma cruzi. By providing this confirmatory tool, the company aimed to improve diagnostic certainty for patients and clinicians, addressing a critical gap in the detection and management of this neglected tropical disease.
In January 2024, SD Biosensor entered into a non-exclusive license agreement with the World Health Organization (WHO) and the Medicines Patent Pool (MPP) to facilitate the local manufacturing of rapid diagnostic tests (RDTs). This collaboration, negotiated under the COVID-19 Technology Access Pool (C-TAP), involved the transfer of the company's proprietary technology and know-how to sub-licensees in low- and middle-income countries. While initially established for pandemic preparedness, the agreement was designed to support the production of diagnostic tests for various neglected tropical diseases and other conditions, including malaria and syphilis, thereby enhancing diagnostic capacity in underserved regions.

Key Market Players

F. Hoffmann-La Roche Ltd
Abbott Laboratories Ltd.
Thermo Fisher Scientific Inc.
ZeptoMetrix LLC
InBios International, Inc.
DiaSys Diagnostics Systems GmbH
Genome Diagnostics Pvt. Ltd.
Omega Diagnostics Group Plc
Oscar Medicare Pvt Ltd.
Coris BioConcept

By Disease	By Diagnostic Method	By Service Type	By End Use	By Region
Dengue Chikungunya Rabies Buruli Ulcer Yaws Lymphatic Filariasis Taeniasis/Cysticercosis Dracunculiasis others	Conventional Molecular/Modern	Centralized Service POC Service	Clinical Labs Hospital/Clinics Home Healthcare	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Neglected Tropical Diseases Diagnosis Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Neglected Tropical Diseases Diagnosis Market, By Disease:

Dengue
Chikungunya
Rabies
Buruli Ulcer
Yaws
Lymphatic Filariasis
Taeniasis/Cysticercosis
Dracunculiasis
others

Neglected Tropical Diseases Diagnosis Market, By Diagnostic Method:

Conventional
Molecular/Modern

Neglected Tropical Diseases Diagnosis Market, By Service Type:

Centralized Service
POC Service

Neglected Tropical Diseases Diagnosis Market, By End Use:

Clinical Labs
Hospital/Clinics
Home Healthcare

Neglected Tropical Diseases Diagnosis Market, By Region:

North America

United States
Canada
Mexico

Europe

France
United Kingdom
Italy
Germany
Spain

Asia Pacific

China
India
Japan
Australia
South Korea

South America

Brazil
Argentina
Colombia

Middle East & Africa

South Africa
Saudi Arabia
UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Neglected Tropical Diseases Diagnosis Market.

Available Customizations:

Global Neglected Tropical Diseases Diagnosis Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Global Neglected Tropical Diseases Diagnosis Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]

Table of content

1. Product Overview

1.1. Market Definition

1.2. Scope of the Market

1.2.1. Markets Covered

1.2.2. Years Considered for Study

1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study

2.2. Baseline Methodology

2.3. Key Industry Partners

2.4. Major Association and Secondary Sources

2.5. Forecasting Methodology

2.6. Data Triangulation & Validation

2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market

3.2. Overview of Key Market Segmentations

3.3. Overview of Key Market Players

3.4. Overview of Key Regions/Countries

3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Neglected Tropical Diseases Diagnosis Market Outlook

5.1. Market Size & Forecast

5.1.1. By Value

5.2. Market Share & Forecast

5.2.1. By Disease (Dengue, Chikungunya, Rabies, Buruli Ulcer, Yaws, Lymphatic Filariasis, Taeniasis/Cysticercosis, Dracunculiasis, others)

5.2.2. By Diagnostic Method (Conventional, Molecular/Modern)

5.2.3. By Service Type (Centralized Service, POC Service)

5.2.4. By End Use (Clinical Labs, Hospital/Clinics, Home Healthcare)

5.2.5. By Region

5.2.6. By Company (2025)

5.3. Market Map

6. North America Neglected Tropical Diseases Diagnosis Market Outlook

6.1. Market Size & Forecast

6.1.1. By Value

6.2. Market Share & Forecast

6.2.1. By Disease

6.2.2. By Diagnostic Method

6.2.3. By Service Type

6.2.4. By End Use

6.2.5. By Country

6.3. North America: Country Analysis

6.3.1. United States Neglected Tropical Diseases Diagnosis Market Outlook

6.3.1.1. Market Size & Forecast

6.3.1.1.1. By Value

6.3.1.2. Market Share & Forecast

6.3.1.2.1. By Disease

6.3.1.2.2. By Diagnostic Method

6.3.1.2.3. By Service Type

6.3.1.2.4. By End Use

6.3.2. Canada Neglected Tropical Diseases Diagnosis Market Outlook

6.3.2.1. Market Size & Forecast

6.3.2.1.1. By Value

6.3.2.2. Market Share & Forecast

6.3.2.2.1. By Disease

6.3.2.2.2. By Diagnostic Method

6.3.2.2.3. By Service Type

6.3.2.2.4. By End Use

6.3.3. Mexico Neglected Tropical Diseases Diagnosis Market Outlook

6.3.3.1. Market Size & Forecast

6.3.3.1.1. By Value

6.3.3.2. Market Share & Forecast

6.3.3.2.1. By Disease

6.3.3.2.2. By Diagnostic Method

6.3.3.2.3. By Service Type

6.3.3.2.4. By End Use

7. Europe Neglected Tropical Diseases Diagnosis Market Outlook

7.1. Market Size & Forecast

7.1.1. By Value

7.2. Market Share & Forecast

7.2.1. By Disease

7.2.2. By Diagnostic Method

7.2.3. By Service Type

7.2.4. By End Use

7.2.5. By Country

7.3. Europe: Country Analysis

7.3.1. Germany Neglected Tropical Diseases Diagnosis Market Outlook

7.3.1.1. Market Size & Forecast

7.3.1.1.1. By Value

7.3.1.2. Market Share & Forecast

7.3.1.2.1. By Disease

7.3.1.2.2. By Diagnostic Method

7.3.1.2.3. By Service Type

7.3.1.2.4. By End Use

7.3.2. France Neglected Tropical Diseases Diagnosis Market Outlook

7.3.2.1. Market Size & Forecast

7.3.2.1.1. By Value

7.3.2.2. Market Share & Forecast

7.3.2.2.1. By Disease

7.3.2.2.2. By Diagnostic Method

7.3.2.2.3. By Service Type

7.3.2.2.4. By End Use

7.3.3. United Kingdom Neglected Tropical Diseases Diagnosis Market Outlook

7.3.3.1. Market Size & Forecast

7.3.3.1.1. By Value

7.3.3.2. Market Share & Forecast

7.3.3.2.1. By Disease

7.3.3.2.2. By Diagnostic Method

7.3.3.2.3. By Service Type

7.3.3.2.4. By End Use

7.3.4. Italy Neglected Tropical Diseases Diagnosis Market Outlook

7.3.4.1. Market Size & Forecast

7.3.4.1.1. By Value

7.3.4.2. Market Share & Forecast

7.3.4.2.1. By Disease

7.3.4.2.2. By Diagnostic Method

7.3.4.2.3. By Service Type

7.3.4.2.4. By End Use

7.3.5. Spain Neglected Tropical Diseases Diagnosis Market Outlook

7.3.5.1. Market Size & Forecast

7.3.5.1.1. By Value

7.3.5.2. Market Share & Forecast

7.3.5.2.1. By Disease

7.3.5.2.2. By Diagnostic Method

7.3.5.2.3. By Service Type

7.3.5.2.4. By End Use

8. Asia Pacific Neglected Tropical Diseases Diagnosis Market Outlook

8.1. Market Size & Forecast

8.1.1. By Value

8.2. Market Share & Forecast

8.2.1. By Disease

8.2.2. By Diagnostic Method

8.2.3. By Service Type

8.2.4. By End Use

8.2.5. By Country

8.3. Asia Pacific: Country Analysis

8.3.1. China Neglected Tropical Diseases Diagnosis Market Outlook

8.3.1.1. Market Size & Forecast

8.3.1.1.1. By Value

8.3.1.2. Market Share & Forecast

8.3.1.2.1. By Disease

8.3.1.2.2. By Diagnostic Method

8.3.1.2.3. By Service Type

8.3.1.2.4. By End Use

8.3.2. India Neglected Tropical Diseases Diagnosis Market Outlook

8.3.2.1. Market Size & Forecast

8.3.2.1.1. By Value

8.3.2.2. Market Share & Forecast

8.3.2.2.1. By Disease

8.3.2.2.2. By Diagnostic Method

8.3.2.2.3. By Service Type

8.3.2.2.4. By End Use

8.3.3. Japan Neglected Tropical Diseases Diagnosis Market Outlook

8.3.3.1. Market Size & Forecast

8.3.3.1.1. By Value

8.3.3.2. Market Share & Forecast

8.3.3.2.1. By Disease

8.3.3.2.2. By Diagnostic Method

8.3.3.2.3. By Service Type

8.3.3.2.4. By End Use

8.3.4. South Korea Neglected Tropical Diseases Diagnosis Market Outlook

8.3.4.1. Market Size & Forecast

8.3.4.1.1. By Value

8.3.4.2. Market Share & Forecast

8.3.4.2.1. By Disease

8.3.4.2.2. By Diagnostic Method

8.3.4.2.3. By Service Type

8.3.4.2.4. By End Use

8.3.5. Australia Neglected Tropical Diseases Diagnosis Market Outlook

8.3.5.1. Market Size & Forecast

8.3.5.1.1. By Value

8.3.5.2. Market Share & Forecast

8.3.5.2.1. By Disease

8.3.5.2.2. By Diagnostic Method

8.3.5.2.3. By Service Type

8.3.5.2.4. By End Use

9. Middle East & Africa Neglected Tropical Diseases Diagnosis Market Outlook

9.1. Market Size & Forecast

9.1.1. By Value

9.2. Market Share & Forecast

9.2.1. By Disease

9.2.2. By Diagnostic Method

9.2.3. By Service Type

9.2.4. By End Use

9.2.5. By Country

9.3. Middle East & Africa: Country Analysis

9.3.1. Saudi Arabia Neglected Tropical Diseases Diagnosis Market Outlook

9.3.1.1. Market Size & Forecast

9.3.1.1.1. By Value

9.3.1.2. Market Share & Forecast

9.3.1.2.1. By Disease

9.3.1.2.2. By Diagnostic Method

9.3.1.2.3. By Service Type

9.3.1.2.4. By End Use

9.3.2. UAE Neglected Tropical Diseases Diagnosis Market Outlook

9.3.2.1. Market Size & Forecast

9.3.2.1.1. By Value

9.3.2.2. Market Share & Forecast

9.3.2.2.1. By Disease

9.3.2.2.2. By Diagnostic Method

9.3.2.2.3. By Service Type

9.3.2.2.4. By End Use

9.3.3. South Africa Neglected Tropical Diseases Diagnosis Market Outlook

9.3.3.1. Market Size & Forecast

9.3.3.1.1. By Value

9.3.3.2. Market Share & Forecast

9.3.3.2.1. By Disease

9.3.3.2.2. By Diagnostic Method

9.3.3.2.3. By Service Type

9.3.3.2.4. By End Use

10. South America Neglected Tropical Diseases Diagnosis Market Outlook

10.1. Market Size & Forecast

10.1.1. By Value

10.2. Market Share & Forecast

10.2.1. By Disease

10.2.2. By Diagnostic Method

10.2.3. By Service Type

10.2.4. By End Use

10.2.5. By Country

10.3. South America: Country Analysis

10.3.1. Brazil Neglected Tropical Diseases Diagnosis Market Outlook

10.3.1.1. Market Size & Forecast

10.3.1.1.1. By Value

10.3.1.2. Market Share & Forecast

10.3.1.2.1. By Disease

10.3.1.2.2. By Diagnostic Method

10.3.1.2.3. By Service Type

10.3.1.2.4. By End Use

10.3.2. Colombia Neglected Tropical Diseases Diagnosis Market Outlook

10.3.2.1. Market Size & Forecast

10.3.2.1.1. By Value

10.3.2.2. Market Share & Forecast

10.3.2.2.1. By Disease

10.3.2.2.2. By Diagnostic Method

10.3.2.2.3. By Service Type

10.3.2.2.4. By End Use

10.3.3. Argentina Neglected Tropical Diseases Diagnosis Market Outlook

10.3.3.1. Market Size & Forecast

10.3.3.1.1. By Value

10.3.3.2. Market Share & Forecast

10.3.3.2.1. By Disease

10.3.3.2.2. By Diagnostic Method

10.3.3.2.3. By Service Type

10.3.3.2.4. By End Use

11. Market Dynamics

11.1. Drivers

11.2. Challenges

12. Market Trends & Developments

12.1. Merger & Acquisition (If Any)

12.2. Product Launches (If Any)

12.3. Recent Developments

13. Global Neglected Tropical Diseases Diagnosis Market: SWOT Analysis

14. Porter's Five Forces Analysis

14.1. Competition in the Industry

14.2. Potential of New Entrants

14.3. Power of Suppliers

14.4. Power of Customers

14.5. Threat of Substitute Products

15. Competitive Landscape

15.1. F. Hoffmann-La Roche Ltd

15.1.1. Business Overview

15.1.2. Products & Services

15.1.3. Recent Developments

15.1.4. Key Personnel

15.1.5. SWOT Analysis

15.2. Abbott Laboratories Ltd.

15.3. Thermo Fisher Scientific Inc.

15.4. ZeptoMetrix LLC

15.5. InBios International, Inc.

15.6. DiaSys Diagnostics Systems GmbH

15.7. Genome Diagnostics Pvt. Ltd.

15.8. Omega Diagnostics Group Plc

15.9. Oscar Medicare Pvt Ltd.

15.10. Coris BioConcept

16. Strategic Recommendations

17. About Us & Disclaimer

Report Description

Table of content

Figures and Tables

Frequently asked questions

What was the market size of the Global Neglected Tropical Diseases Diagnosis Market in 2025?

Which is the dominating region in the Global Neglected Tropical Diseases Diagnosis Market?

Which is the fastest growing segment in the Global Neglected Tropical Diseases Diagnosis Market?

What is the expected growth rate of the Global Neglected Tropical Diseases Diagnosis Market?